v3.26.1
Consolidated Condensed Statements of Operations and Comprehensive Income - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 27, 2026
Jun. 28, 2025
Jun. 27, 2026
Jun. 28, 2025
Income Statement [Abstract]        
Net sales $ 153,208 $ 147,660 $ 285,297 $ 271,536
Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively) 47,542 45,570 88,862 86,390
Gross profit 105,666 102,090 196,435 185,146
Selling, general and administrative expense 82,740 79,110 161,065 152,612
Research and development expense 3,173 3,172 5,640 6,183
Restructuring costs (415) 0 39 0
Depreciation and amortization 1,041 1,439 2,148 3,032
Loss on disposals 0 1 0 82
Operating income 19,127 18,368 27,543 23,237
Interest expense, net 4,068 7,494 8,394 15,003
Other (income) expense (249) 561 (676) 1,338
Other expense 3,819 8,055 7,718 16,341
Income before income taxes 15,308 10,313 19,825 6,896
Income tax (benefit) expense, net (20,897) 1,041 (20,326) 946
Net income 36,205 9,272 40,151 5,950
Income attributable to noncontrolling interest (2,764) (1,813) (3,597) (1,128)
Net income attributable to Bioventus Inc. 33,441 7,459 36,554 4,822
Change in foreign currency translation adjustments 243 1,593 (1,225) 2,226
Change in the fair value of cash flow hedges 928 0 1,928 0
Comprehensive income 37,376 10,865 40,854 8,176
Comprehensive income attributable to noncontrolling interest (2,984) (2,118) (3,728) (1,555)
Comprehensive income attributable to Bioventus Inc. $ 34,392 $ 8,747 $ 37,126 $ 6,621
Income per share of Class A common stock:        
Basic (in dollars per share) $ 0.49 $ 0.11 $ 0.54 $ 0.07
Diluted (in dollars per share) $ 0.47 $ 0.11 $ 0.52 $ 0.07
Weighted-average shares of Class A common stock outstanding:        
Basic (in shares) 67,869,148 66,500,433 67,589,178 66,258,679
Diluted (in shares) 70,838,486 68,536,759 70,429,825 68,765,591